A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

September 17, 2014

Primary Completion Date

August 22, 2017

Study Completion Date

August 22, 2017

Conditions
EbolaEbola Zaire
Interventions
BIOLOGICAL

cAd3-EBO Z at 1 x 10^10 vp

Low dose cAd3-EBO Z

BIOLOGICAL

cAd3-EBO Z at 2.5 x 10^10 vp

Medium dose cAd3-EBO Z

BIOLOGICAL

cAd3-EBO Z at 5 x 10^10 vp

High dose cAd3-EBO Z

BIOLOGICAL

4.4x10^8 TCID50s MVA-BN® Filo

High dose MVA-BN® Filo

BIOLOGICAL

2.2x10^8 TCID50s MVA-BN® Filo

Low dose MVA-BN® Filo

BIOLOGICAL

4.4 x 10^7 TCID50s MVA-BN® Filo

Very low dose MVA-BN® Filo

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford

All Listed Sponsors
collaborator

Wellcome Trust

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Oxford

OTHER

NCT02240875 - A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo | Biotech Hunter | Biotech Hunter